1. Home
  2. NGNE vs FISI Comparison

NGNE vs FISI Comparison

Compare NGNE & FISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$23.57

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo Financial Institutions Inc.

FISI

Financial Institutions Inc.

SELL

Current Price

$39.50

Market Cap

757.7M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
NGNE
FISI
Founded
2003
1817
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
757.7M
IPO Year
2014
1999

Fundamental Metrics

Financial Performance
Metric
NGNE
FISI
Price
$23.57
$39.50
Analyst Decision
Strong Buy
Hold
Analyst Count
10
2
Target Price
★ $77.88
$45.00
AVG Volume (30 Days)
★ 354.4K
108.8K
Earning Date
11-12-2026
10-29-2026
Dividend Yield
N/A
★ 3.26%
EPS Growth
0.93
★ 231.27
EPS
N/A
★ 2.08
Revenue
N/A
N/A
Revenue This Year
N/A
$6.51
Revenue Next Year
N/A
$4.63
P/E Ratio
★ N/A
$18.88
Revenue Growth
N/A
★ N/A
52 Week Low
$15.93
$25.83
52 Week High
$43.66
$42.97

Technical Indicators

Market Signals
Indicator
NGNE
FISI
Relative Strength Index (RSI) 33.88 47.60
Support Level $16.88 $37.89
Resistance Level $29.16 $40.33
Average True Range (ATR) 1.99 0.85
MACD -0.13 0.03
Stochastic Oscillator 29.31 61.66

Price Performance

Historical Comparison
NGNE
FISI

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About FISI Financial Institutions Inc.

Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.

Share on Social Networks: